Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 7 of 95, showing 5 Applications out of 474 total, starting on record 31, ending on 35

# Protocol No Study Title Investigator(s) & Site(s)

31.

ECCT/24/02/06   INAVO122
    A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

32.

ECCT/24/02/05   Doxo-study
    Pharmacokinetic profiles for Doxorubicin among children with childhood cancer in Kenya.           
Principal Investigator(s)
1. Festus MUIGAI Njunguna
Site(s) in Kenya
MOI UNIVERSITY SCHOOL OF MEDICINE
 
View

33.

ECCT/24/02/04   IGHID 12333
    IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.IGHID 12333: Phase I study on the Pharmacokinetics of intravaginal, self-administered Artesunate vaginal pessaries among women in Kenya.   
Principal Investigator(s)
1. Chemtai Mungo
Site(s) in Kenya
Lumumba subcounty Hospital Kisumu
 
View

34.

ECCT/24/02/03   MPZ-MAL-01
    A Phase 2a, Multicenter, Open-label, Dose-finding, Dose Escalation Study of Meplazumab in Adult Patients Diagnosed with   Uncomplicated Plasmodium falciparum Malaria       
Principal Investigator(s)
1. Videlis Nduba
Site(s) in Kenya
1. Kenya Medical Research Institute(KEMRI):Siaya Clinical Research Annex (Siaya county)
2. Victoria Biomedical Research Institute (VIBRI) (Kisumu county)
3. AHERO CLINICAL TRIALS UNIT (Kisumu county)
 
View

35.

ECCT/24/02/02   Sabin 003
    A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral-Vectored Sudan Ebolavirus Vaccine in Healthy Adults   
Principal Investigator(s)
1. Prof. Videlis Nduba Nzioka
Site(s) in Kenya
KEMRI / CRDR, KEMRI Clinical Research Annex, Siaya County Referral Hospital Ground. P.O BOX 144-40600 ,Siaya, Kenya
 
View